TuHURA Biosciences, Inc. (HURA)

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company developing therapies intended to overcome resistance to cancer immunotherapy. The company became publicly traded through a merger with Kintara Therapeutics.

Its lead product candidate, IFx-2.0, is an innate immune agonist designed to make tumors more visible to the immune system so that checkpoint inhibitors can work more effectively. It has been studied in combination with an approved checkpoint inhibitor as a first-line treatment for advanced Merkel cell carcinoma. TuHURA is also developing bi-functional antibody-drug conjugates and other approaches targeting immune-suppressive cells in the tumor microenvironment.

The company is headquartered in Tampa, Florida, and its common stock trades on the Nasdaq.